VCYT Relative Valuation
VCYT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VCYT is overvalued; if below, it's undervalued.
Historical Valuation
Veracyte Inc (VCYT) is now in the Fair zone, suggesting that its current forward PS ratio of 4.14 is considered Fairly compared with the five-year average of -22.76. The fair price of Veracyte Inc (VCYT) is between 19.51 to 66.66 according to relative valuation methord.
Relative Value
Fair Zone
19.51-66.66
Current Price：25.17
Fair
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.65
P/B
Median3y
1.81
Median5y
2.72
3.76
FCF Yield
Median3y
1.29
Median5y
0.35
Competitors Valuation Multiple
The average P/S ratio for VCYT's competitors is 2.96, providing a benchmark for relative valuation. Veracyte Inc Corp (VCYT) exhibits a P/S ratio of 4.14, which is 39.72% above the industry average. Given its robust revenue growth of 18.20%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Veracyte Inc (VCYT) currently overvalued or undervalued?
What is Veracyte Inc (VCYT) fair value?
How does VCYT's valuation metrics compare to the industry average?
What is the current P/B ratio for Veracyte Inc (VCYT) as of Jul 17 2025?
What is the current FCF Yield for Veracyte Inc (VCYT) as of Jul 17 2025?
What is the current Forward P/E ratio for Veracyte Inc (VCYT) as of Jul 17 2025?